Jul 23, 2024 | Federal Trade Commission (FTC), Formularies, News, Pharmacy Benefits Manager (PBM)
In an interim report released on July 9, the Federal Trade Commission charges major pharmacy benefit managers of engaging in business practices designed to benefit their own bottom lines at the expense of clients. The FTC report, subtitled “The Powerful...
Apr 1, 2024 | Benefits preservation, Comparative Effectiveness, Cost Savings, Drug costs, MedBen Rx, Pharmacies, Pharmacy Benefits Manager (PBM), Rx Costs, Savings, Specialty Drugs, Transparency
Employers are turning away from the “big three” pharmacy benefits managers to other PBMs that offer greater transparency and lower costs, says Wharton professor of health care management Lawton Robert Burns. As one of those alternatives, MedBen Rx is...
Feb 6, 2024 | Claims, Cost Savings, Drug costs, Gene therapy, Genetic testing, MedBen Rx, MedBen University, News, Pharmacogenomics, Pharmacy Benefits Manager (PBM), Rx Costs, Specialty Drugs
MedBen recently had the honor to welcome some of the most respected names in the benefits management industry. At the invitation-only 2024 Benefits Advisory Conference on January 26, attending brokers learned about health plan innovations that will help self-funded...
Oct 3, 2023 | MedBen Rx, Pharmacy Benefits Manager (PBM), Rebates, White paper
In their continuing quest for bigger profits, major pharmacy benefit managers (PBMs) have adapted a new tactic: clever wordplay. What was once known as a “rebate” – a partial refund of the drug payment back to the plan – now goes by a variety of other...
Jul 11, 2023 | Brand Name Drugs, Generic Drugs, MedBen Rx, Pharmacies, Pharmacy Benefits Manager (PBM), Prescription drugs, Rx Costs, Rx prices, Rx Spending, Savings, Specialty Drugs, Transparency, Value
A new playbook from the National Alliance of Healthcare Purchaser Coalitions lists the top 10 concerns employer health plans have with pharmacy benefit managers (PBMs): Promoting drugs with higher prices when lower-price options are availableOffering preferred...
Mar 21, 2023 | Brand Name Drugs, Diabetes, Generic Drugs, MedBen Rx, MedBen University, Pharmacy Benefits Manager (PBM), Prescription drugs, Rx Costs, Rx prices, Savings
Earlier this month, drug manufacturer Eli Lilly announced that it cutting the cost of two of its prescription brand insulins, Humalog and Humulin, by 70%, and capping out-of-pocket costs for privately insured patients at $35 a month. Competing...
